Clinical Insights: COVID-19 and the Liver

Highlights and Discussion of AASLD’s paper “Clinical Insights for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic" Released March 23, 2020
Submit your questions in the Q&A box at the top or bottom of your screen.

Questions will be answered at the end of the presentation.
Moderators

Raymond T. Chung, MD, FAASLD
AASLD President-Elect

K. Rajender Reddy, MD, FAASLD
Presenters

Oren K. Fix, MD, MSc, FAASLD

Bilal Hameed, MD
 bully Welcome
  • Ray Chung, MD, FAASLD

• Introduction
  • Raj Reddy, MD, FAASLD

o Clinical Insights Debrief
  • Oren Fix, MD, FAASLD
  • Bilal Hameed, MD

o Questions and Answers

o Summary
AASLD and COVID-19: rationale

- Potential for direct infection of the liver
- Elevated AST/ALT frequent
- Complications of ARDS and CRS → liver
- Hepatotoxic therapies
- Unique potential susceptibilities in CLD, post-transplant, AIH on immunosuppressives
- Risks of transplantation during COVID-19
- Need for guidance for providers
AASLD COVID-19 Working Group

- Raj Reddy
- Oren Fix
- Bilal Hameed
- Michael Schilsky
- Mark Russo
- Brendan McGuire
- Bob Fontana
- Ryan Kwok
- David Mulligan
- Dan Pratt
- Jorge Bezerra
- Ray Chung
Clinical Insights: COVID-19 and the Liver

Introduction

K. Rajender Reddy, M.D.
Ruimy Family President’s Distinguished Professor in Medicine
Director of Hepatology
Medical Director, Liver Transplantation
University of Pennsylvania
What is SARS-CoV-2/COVID-19?

- SARS-CoV-2 is a novel enveloped RNA betacoronavirus first identified in Wuhan, China
  - Similar to SARS-CoV
  - Causes an infectious respiratory disease - COVID-19
  - Shown to be especially severe in older individuals and those with underlying medical problems

---

**Timeline of Key Events**

- **Dec 30, 2019**: Cluster of pneumonia cases with unknown origin reported to China NHC
- **Jan 7, 2020**: Novel coronavirus isolated
- **Jan 11, 2019**: First fatality reported
- **Jan 12, 2020**: Named as 2019-nCoV; genome made publically available
- **Jan 13, 2020**: First reported case outside China (Thailand)
- **Jan 20, 2020**: First reported case in the U.S. (traveler from Wuhan)
- **Jan 30, 2020**: W.H.O declares global health emergency
- **Feb 11, 2020**: W.H.O names disease COVID-19
- **Feb 26, 2020**: CDC confirms first possible instance of community spread in U.S.
- **Mar 11, 2020**: W.H.O declares COVID-19 global pandemic
- **Mar 13, 2020**: Europe becomes epicenter of the pandemic
- **Mar 16, 2020**: President Trump issues guidelines urging social distancing and discouraging gatherings >10 people

---

An early study of 138 hospitalized patients with confirmed COVID-19 in Wuhan, China described the most common symptoms as:

- **Fever (98.6%)**
- **Fatigue (69.6%)**
- **Dry cough (59.4%)**
- **Anorexia (39.9%)**
- **Myalgia (34.8%)**
- **Dyspnea (31.2%)**
- **Expectoration (26.8%)**
- **Pharyngalgia (17.4%)**
- **Diarrhea (10.1%)**
- **Nausea (10.1%)**

A larger study with 1099 patients with confirmed COVID-19 in 30 provinces in China found:

- 43.8% had fever on admission but 88.7% had a fever during hospitalization
- **Cough (67.8%)**
- **Fatigue (38.1%)**
- **Sputum production (33.7%)**

The Chinese Center for Disease Control and Prevention reported:

- **80.9% of cases were mild** (non-pneumonia and mild pneumonia cases)
- **13.8% of cases were severe** (dyspnea, respiratory frequency ≥ 30/minute, blood oxygen saturation ≤93%, PaO2/FiO2 ratio <300, and/or lung infiltrates >50% within 24–48 hours)
- **4.7% of cases were critical** (respiratory failure, septic shock, and/or multiple organ dysfunction/failure)

Incubation period average was 4-5 days (up to 14)

World Wide Cases
454,000+ cases worldwide
20,500+ deaths

In the United States:
• 61,000+ cases
• 800+ deaths

New York is the new U.S. epicenter:
• 30,000+ cases in NY state
• 17,000+ cases in NYC

USA now has 10,000+
new cases per day

https://coronavirus.jhu.edu/map.html as of 3:30pm 3/25/2020
Populations at Risk

Early reports from China (cases reported to China’s Infectious Disease Information System through Feb 11, 2020) show increased fatality rates for individuals who are older and with comorbid conditions\(^1\):

- **70-79**: 8% fatality rate
- **≥80**: 14.8% fatality rate

Preliminary reports by the CDC indicate in the US fatality is highest among individuals **≥85 (10-27)%**\(^2\)

<table>
<thead>
<tr>
<th>Comorbid Condition</th>
<th>Confirmed Cases</th>
<th>Deaths</th>
<th>Case Fatality Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>44,672</td>
<td>1,023</td>
<td>2.3%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2,683</td>
<td>161</td>
<td>6%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1,102</td>
<td>80</td>
<td>7.3%</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>873</td>
<td>92</td>
<td>10.5%</td>
</tr>
<tr>
<td>Chronic respiratory Disease</td>
<td>511</td>
<td>32</td>
<td>6.3%</td>
</tr>
<tr>
<td>Cancer (any)</td>
<td>107</td>
<td>6</td>
<td>5.6%</td>
</tr>
<tr>
<td>None</td>
<td>15,536</td>
<td>133</td>
<td>0.9%</td>
</tr>
<tr>
<td>Missing</td>
<td>23,690</td>
<td>617</td>
<td>2.6%</td>
</tr>
</tbody>
</table>

The Centers for Disease Control states individuals at higher risk for severe illness include:

- People aged 65 years and older
- People who live in a nursing home or long-term care facility
- Other high-risk conditions could include:
  - People with chronic lung disease or moderate to severe asthma
  - People who have serious heart conditions
  - People who are immunocompromised including cancer treatment
  - People of any age with severe obesity (body mass index [BMI] >40) or certain underlying medical conditions, particularly if not well controlled, such as those with diabetes, renal failure, or **those with liver disease might also be at risk**

2. CDC, 2020; MMWR Morb Mortal Wkly Rep. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e2external icon

Clinical Insights: COVID-19 and the Liver

Oren K. Fix, MD, MSc, FAASLD
Medical Director, Liver Transplant Program
Swedish Medical Center, Seattle, WA

Clinical Associate Professor
Washington State University Elson S. Floyd
College of Medicine
- Effects of SARS-CoV-2 on the Liver and Evaluation of COVID-19 Patients with Elevated Liver Biochemistries

- Stable Outpatients with Liver Disease or Hepatocellular Carcinoma

- Patients with Decompensated Cirrhosis, Liver Transplant Evaluations, and Patients on the Liver Transplant Waiting List

- Liver Transplantation, Resource Utilization, and Ethical Considerations
Effects of SARS-CoV-2 on the Liver
Evaluation of COVID-19 Patients with Elevated Liver Biochemistries
What we know:

- SARS-CoV-2 binds to ACE2 to gain entry into cells
  - Found on liver and biliary epithelial cells
- Incidence of elevated liver tests in hospitalized COVID-19 patients: 14%-53%, AST/ALT > bilirubin
- Liver injury more common in more severe COVID-19 cases than mild cases, rare cases of acute liver injury
- Severe COVID-19 is uncommon in children and less likely to be associated with elevated liver tests
- Low serum albumin is a marker of COVID-19 severity
- Liver histology ranges from moderate microvesicular steatosis + mild lobular/portal activity to focal necrosis

Xu L et al. Liver Int 2020
Zhe et al. Lancet Respir Med 2020
Yao XH et al. Chinese J Path 2020
What we don’t know:

- Elevated liver tests in COVID-19: Direct viral effect or secondary to inflammatory/immune response or drug hepatotoxicity?
- Are patients with chronic liver disease (HBV, HCV, fatty liver) more susceptible to liver injury from SARS-CoV-2?
- Does SARS-CoV-2 exacerbate cholestasis in patients with PBC or PSC?
Recommendations:

- Test for HBV and HCV in patients with COVID-19 and elevated liver tests
- Avoid unnecessary imaging unless there is a clinical suspicion for biliary obstruction, cholangitis, etc.
- Patients with COVID-19 and elevated liver tests should still be considered for investigational/off-label therapeutics
- Monitor liver tests in all COVID-19 patients, especially if treated with remdesivir or tocilizumab
- Don’t assume AIH flare or rejection in patients with elevated liver tests and COVID-19
- Evaluate children with COVID-19 and elevated liver tests for underlying liver disease: Do not assume COVID-19
Stable Outpatients with Liver Disease or Hepatocellular Carcinoma
What we know:

- Asymptomatic patients can contribute to SARS-CoV-2 spread (immunocompetent and immunosuppressed)
- Children less likely to become ill but can still be infectious

What we don’t know:

- Are patients with HCC at increased risk for severe COVID-19?
Recommendations:

- Severely limit outpatient visits to urgent issues and clinically significant liver disease (e.g., jaundice, ALT or AST >500, recent decompensation)
- Stagger patient arrival times, room patients immediately
- Limit family/friends who accompany patients
- Use phone visits or telemedicine
- Screen all patients for symptoms/fever or recent exposure before entry to clinic space
- Check each patient’s temperature when they arrive
- Consider cohorting patients with COVID-19 symptoms
- Do not evaluate patients with COVID-19 symptoms/fever in the hepatology/liver transplant clinic

Recommendations (HCC):

- Consider reviewing images of new referral for liver masses in tumor board or with expert radiologists before scheduling in-person visit
- Continue usual surveillance imaging in patients with cirrhosis, HBV or HCC
  - An arbitrary delay of 2 months is reasonable and may be necessary
- Proceed with HCC treatments
Patients with Decompensated Cirrhosis
Liver Transplant Evaluations
Patients on the Transplant Waiting List
What we know:
- Nearly all OPOs now test for SARS-CoV-2 RNA
- Test performance is not perfect:
  - Sensitivity: nasal (63%), pharyngeal (32%), BAL (93%)
- Capacity for testing may be limited
- Moving target: rapid tests including antibody tests being developed

What we don’t know:
- What are the effects of SARS-CoV-2 in patients with chronic liver disease, decompensated cirrhosis or those awaiting liver transplantation?

Wang W et al. JAMA 2020
**Recommendations:**

- Limit the number of patients coming to clinic for transplant evaluations
- Use telemedicine/telephone: patient education, social work/dietitian/financial consults, outreach clinics
- Avoid multiple patients in one room for patient education
- Obtain labs and imaging only as clinically necessary
  - Know recent [OPTN policy changes](https://unos.org/covid/)
- Ensure patients have adequate supplies of medications
  - 90-day supplies instead of 30-day supplies
- Instruct patients to avoid community recovery support meetings (e.g., AA): Provide telephone/online resources
- Instruct patients not to travel

[https://unos.org/covid/](https://unos.org/covid/)
Liver Transplantation, Resource Utilization, and Ethical Considerations
**What we know:**

- Resource utilization and ethical considerations: *We’ve got this*

- CMS includes transplant surgery in **Tier 3b**: *“Do not postpone”*

- People who test positive for SARS-CoV-2 are medically ineligible for organ donation


What we don’t know:

- Which life is more valuable and in need of limited resources: COVID-19 patient or patient with urgent need of liver transplantation?
- Is it ethical to start a patient on immunosuppression now?
- Are immunosuppressed patients at higher risk of severe COVID-19?
- Will we need to ration transplants? How do we prioritize?
**Recommendations:**

- Start thinking about these challenging issues now and develop a policy in your program.
- Ensure your administrators are aware of the **CMS Tier 3b** designation.
- Consider resource utilization in the decision to proceed with liver transplantation (ICU beds, ventilators, PPE, blood).
- COVID-19 prevalence and resources vary across the country.


**Recommendations:**

- Screen potential donors for exposure and COVID-19 symptoms/fever (regardless of test results or test availability)
- Screen recipients for COVID-19 symptoms/fever and exposure before they are called in from home for transplantation
- Consider testing asymptomatic recipients and donors for SARS-CoV-2 before transplantation, if available
- Consider suspending living donor liver transplant programs (exceptions: pediatric patients with ALF)
- Consult local medical ethics committees

---

© 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

WWW.AASLD.ORG
Clinical Insights: COVID-19 and the Liver

Bilal Hameed, MD
Hepatology Clinic Chief

Associate Professor of Medicine
University of California San Francisco, CA
- Post-Liver-Transplant Patients
- Management of Patients on Immunosuppressive Agents
- Inpatients
- Medication Management of Patients with COVID-19
- Procedures
Post-Liver-Transplant Patients
Post Liver Transplant Patients

**What we know:**
- Post-transplant recipients aged >60 years and immunosuppressed patients are more likely to acquire SARS-CoV-2 infection.
- Too early to know if immunosuppressed patients are at greater risk for severe COVID-19.
- Immunosuppression may prolong viral shedding.

**Recommendations:**
- Emphasize prevention measures.
- Minimize in-person visits for post-transplant patients by maximizing use of telemedicine.
- Advise against travel.
- Consider advocating for telework or excuses from work for transplant patients and their primary care givers.

Management of Patients on Immunosuppressive Agents
Management on Immunosuppressive Agents

What we know:

• The effects of immunosuppression on COVID-19 are not well established.
• Reducing or stopping immunosuppressants may cause a flare of autoimmune hepatitis or precipitate acute rejection.
• The WHO recommends avoiding corticosteroids for treatment of COVID-19 unless indicated for another therapeutic purpose.

Recommendations:

Patients without COVID-19:
• Not to routinely reduce immunosuppression.

Patients with COVID-19:
• Consider minimizing the dosage of high-dose prednisone but maintain a dosage to avoid adrenal insufficiency.
• Consider reducing but not stopping calcineurin inhibitor or mycophenolate, especially in the setting of lymphopenia, fever or pneumonia attributed to COVID-19.
• Use caution in initiating prednisone or immunosuppressive therapy where the potential benefit might be outweighed by the risks (e.g alcoholic hepatitis).

Inpatients
**What we know:**

- Healthcare workers are at risk for COVID-19.
- Minimizing interactions among healthcare workers and between patients and healthcare workers is critical to reducing the spread of SARS-CoV-2.
- Minimizing the transport of patients within facilities could reduce the spread of SARS-CoV-2.

**Recommendations:**

- Consider developing a policy for review and triage of hospital inpatient transfers.
- Avoid direct admission for patients with fever or respiratory symptoms.
- Consider COVID-19 in patients with new onset HE.
- Aggressive airway management in COVID-19 patients with liver-related pulmonary disease (e.g., hydrothorax, PoPH, HPS).

Medication Management of Patients with COVID-19 and Potential Drug-Drug Interactions
### Potential Treatment Regimens

**NO APPROVED DRUGS**

<table>
<thead>
<tr>
<th>Possible role</th>
<th>No role (except specific other need)</th>
</tr>
</thead>
</table>
| • Remdesivir*  
• IL-6 receptor blockers (e.g. tocilizumab)*  
• (Hydroxy)chloroquine and azithromycin  
• Darunavir/Cobicistat  
• Convalescent plasma  
• Favipiravir | • Lopinavir/ritonavir  
• Steroids  
• ACE-inhibitors  
• Oseltamivir |

Concern for drug-drug interactions and safety

* ALT/AST >5xULN, exclusion or stopping criteria
Medication Management of Patients with COVID-19

What we know:

• RCT of lopinavir-ritonavir in severe COVID-19 showed no clinical benefit.
• Lopinavir-ritonavir are potent inhibitors of CYP3A4.
• The European Society of Cardiology recommends continuation of usual antihypertensive therapy, including ACEIs and ARBs.

Recommendations:

• The evidence does not support the use of lopinavir-ritonavir for COVID-19.
• Patients on chronic ACEIs/ARBs should remain on them even in the setting of COVID-19.
• Acetaminophen ≤2 g/d is the preferred analgesic and antipyretic.
• Monitor liver chemistries in all COVID-19 patients, especially if treated with remdesivir or tocilizumab.

## Potential Drug-Drug Interactions

### Interactions with Experimental COVID-19 Therapies

Charts updated 20 March 2020

Please check [www.covid19-druginteractions.org](http://www.covid19-druginteractions.org) for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

### Immunosuppressants

<table>
<thead>
<tr>
<th></th>
<th>ATV</th>
<th>LPV/r</th>
<th>RDV</th>
<th>FAVI</th>
<th>CLQ</th>
<th>HCLQ</th>
<th>NITAZ</th>
<th>RBV</th>
<th>TCZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td>↔</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Anti-thymocyte globulin</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td>↔</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Basiliximab</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Belatacept</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
<td></td>
<td></td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>↔</td>
<td>↑↓</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
<td></td>
<td></td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
<td></td>
<td></td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>↑</td>
<td>↑</td>
<td>↔</td>
<td>↔</td>
<td>↑</td>
<td></td>
<td></td>
<td>↑</td>
<td>↓</td>
</tr>
</tbody>
</table>
Procedures
Recommendations:

- Cancel all elective/non-urgent procedures (e.g., endoscopy, liver biopsy and fibroscan).
- Procedures can be performed
  1. Liver biopsy (rejection or AIH).
  2. Therapeutic paracentesis.
  3. TIPS.
  4. Endoscopy for variceal bleeding, or secondary prophylaxis
  5. Biliary procedures.
- Use appropriate personal protective equipment (PPE)
- Consider limiting the involvement of fellows in endoscopies.

What we know:

- Endoscopic procedures should be considered aerosol-generating.
- Potential for fecal-oral SARS-CoV-2 transmission and the virus is detected in saliva.
- The joint GI societies recommend to “strongly consider rescheduling non-urgent endoscopic procedures.”

Questions?

Please submit your questions to the Q&A Chat now.
AASLD’s COVID-19 Resources


Join/Engage: COVID-19 Care Community on AASLD’s online community, Engage. Open to all members. Log in to Engage with your AASLD user name and password.

Submit: Hepatology, Liver Transplantation, Hep Commun all accepting and fast tracking review of COVID-19 original articles, case reports

© 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG